Finally, to evaluate the clinical significance of our findings, we performed immunohistochemistry (IHC) staining of breast cancer tissue microarray slides (TMAs) using anti-CD163 (TAM marker), anti-ZEB1 and anti-DNMT1 antibodies. This evidence concerns the gene CD163 and breast cancer.